# Theriva Biologics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Theriva Biologics, Inc.). ## Overview Theriva Biologics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases. Its pipeline centers on oncolytic adenovirus programs, including VCN-01, along with earlier-stage assets and manufacturing technologies for viral therapeutics. ## Products & services • VCN-01 oncolytic adenovirus for solid tumors • VCN-X next-generation oncolytic adenovirus platform • SYN-004 (ribaxamase) for antibiotic-related complications • SYN-020 for gastrointestinal and inflammatory indications • THERICEL suspension cell lines for viral manufacturing • Patent- and license-based biotech development programs - **Oncolytic adenovirus therapeutics** (70%) — Clinical-stage virus-based cancer therapies designed to selectively replicate in tumor cells and enhance anti-tumor response. - **Non-oncology therapeutic candidates** (15%) — Earlier-stage programs such as ribaxamase and SYN-020 targeting antibiotic-related and gastrointestinal diseases. - **Viral manufacturing technology** (10%) — THERICEL cell-line platform and related know-how for manufacturing viral and gene therapy products. - **Licensing and collaboration arrangements** (5%) — Out-licensing and partnered development rights for selected programs and technologies. - VCN-01 oncolytic adenovirus for solid tumors - VCN-X next-generation oncolytic adenovirus platform - SYN-004 (ribaxamase) for antibiotic-related complications - SYN-020 for gastrointestinal and inflammatory indications - THERICEL suspension cell lines for viral manufacturing - Patent- and license-based biotech development programs ## Customers Theriva does not sell commercial medicines at scale; its primary counterparties are clinical trial sites, research collaborators, and potential licensing or development partners. In oncology, the end users are patients with high-unmet-need cancers such as pancreatic cancer, retinoblastoma, and other solid tumors, while future commercialization would depend on hospitals, oncology centers, and specialty distributors. - **Clinical trial investigators and sites** (primary) — They administer VCN-01 and other pipeline studies and are essential for patient enrollment and data generation. - **Patients with high-unmet-need cancers** (primary) — They are the intended recipients of oncolytic adenovirus therapies such as VCN-01 in pancreatic cancer and retinoblastoma. - **Biopharma licensing partners** (secondary) — They may license programs such as SYN-020 or collaborate on development and commercialization. - **Research and manufacturing collaborators** (secondary) — Academic and government partners support platform work such as THERICEL and AAV manufacturing adaptation. - Clinical trial investigators and study sites running oncology studies - Patients with pancreatic cancer, retinoblastoma, and solid tumors - Pharma/biotech partners licensing or co-developing pipeline assets - Research institutions collaborating on viral manufacturing platforms - Future oncology treatment centers if any product reaches market ## Geography Theriva is headquartered in the United States but its business is materially international because its core oncology platform originated through the acquisition of Theriva Biologics, S.L. in Spain. Its development work, patents, and collaborations span the U.S. and Europe, and clinical programs may enroll patients across multiple countries depending on trial design. - United States headquarters and primary corporate base - Spain is important through the acquired Theriva Biologics, S.L. platform - European collaborations support manufacturing and gene-therapy work - Clinical trials may recruit internationally depending on indication - No disclosed country revenue mix because the company is pre-commercial ## Strategy Theriva’s strategy is to advance VCN-01 as its lead oncology asset while building optionality through next-generation virus platforms and manufacturing technologies. The company also seeks partnerships and licensing arrangements to fund development, extend its pipeline, and reduce the capital burden of later-stage clinical programs. - **Advance VCN-01 clinical development** (short-term) — VCN-01 is the lead asset and the main source of future value creation. - **Pursue partnering and licensing** (short-term) — External funding and commercialization partners can reduce capital needs. - **Build next-generation and manufacturing platforms** (medium-term) — VCN-X and THERICEL can broaden the technology base beyond a single asset. - Advance VCN-01 through clinical development in high-unmet-need cancers - Develop VCN-X to improve tumor killing and systemic delivery - Use partnerships and licensing to fund non-core programs - Expand THERICEL as a manufacturing platform for viral therapies - Protect the platform with patents and exclusive licenses ## Risks Theriva is exposed to the typical risks of a clinical-stage biotech company: clinical trial failure, regulatory delay, and dependence on external funding. Its concentration in a small number of experimental programs, plus competition from better-capitalized oncology developers, makes execution risk especially important. - **Clinical development failure** [high] — VCN-01 and other programs are unproven and depend on trial outcomes. - **Funding and going-concern pressure** [critical] — Later-stage trials require substantial capital and no committed financing is assured. - **Competitive displacement** [high] — Larger biotech and pharma firms can reach approval faster and with more resources. - **Regulatory and trial-enrollment risk** [medium] — Approval timelines and patient recruitment can slow or stop development programs. - **Data security and privacy exposure** [medium] — Clinical trial and patient data are sensitive and subject to privacy rules. - Clinical programs may fail to show efficacy or safety - Additional financing may be unavailable on acceptable terms - Competition from larger oncology and OV developers is intense - IPR&D and goodwill values depend on clinical progress - Cybersecurity and data privacy risks affect trial operations ## Accounting The most important accounting judgments are valuation of in-process R&D, goodwill, and contingent consideration, all of which depend heavily on clinical success assumptions and discount rates. Because the company is pre-commercial, research and development spending and impairment testing can materially change reported results from period to period. - **In-process R&D valuation** — Can create large non-cash impairment charges - **Goodwill impairment** — Affects reported earnings and equity - **Contingent consideration** — Can introduce volatility in operating results - **R&D expense recognition** — Drives period-to-period operating loss volatility - IPR&D valuation depends on clinical probability and discount rates - Goodwill impairment can be triggered by stock-price declines - Contingent consideration requires fair-value estimates - R&D expense timing affects quarterly comparability - License and collaboration terms may affect future revenue recognition --- *Last updated: 2026-04-29T05:03:41.217279+00:00*